Singapore markets open in 7 hours 50 minutes

GILD Feb 2023 80.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
6.60+1.60 (+32.00%)
As of 11:31AM EST. Market open.
Full screen
Previous close5.00
Open5.40
Bid6.50
Ask6.65
Strike80.00
Expiry date2023-02-17
Day's range5.40 - 6.75
Contract rangeN/A
Volume26
Open interest1.42k
  • Motley Fool

    Is Gilead Sciences a Good Stock to Buy Now?

    Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations. A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy. Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy.

  • Zacks

    Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

    Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

  • Business Wire

    U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

    FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in